The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Pricing in the Market for Anticancer Drugs
Open accessAbstract
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab—brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the launch prices of new anticancer drugs and other drugs in the so-called “specialty” pharmaceutical market have been increasing over time and that increases are unrelated to the magnitude of the expected health benefits. In this paper, we discuss the unique features of the market for anticancer drugs and assess trends in the launch prices for 58 anticancer drugs approved between 1995 and 2013 in the United States. We restrict attention to anticancer drugs because the use of median survival time as a primary outcome measure provides a common, objective scale for quantifying the incremental benefit of new products. We find that the average launch price of anticancer drugs, adjusted for inflation and health benefits, increased by 10 percent annually—or an average of $8,500 per year—from 1995 to 2013. We argue that the institutional features of the market for anticancer drugs enable manufacturers to set the prices of new products at or slightly above the prices of existing therapies, giving rise to an upward trend in launch prices. Government-mandated price discounts for certain classes of buyers may have also contributed to launch price increases as firms sought to offset the growth in the discount segment by setting higher prices for the remainder of the market.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · American Economic Review · doi:10.1257/aer.103.6.i · Cited by 7,220
Mental Accounting and Consumer Choice
Thaler, R. (1985) · Marketing Science · doi:10.1287/mksc.4.3.199 · Cited by 4,885
Mental Accounting and Consumer Choice
Thaler, R. H. (2008) · Marketing Science · doi:10.1287/mksc.1070.0330 · Cited by 3,415
Fairness as a Constraint on Profit Seeking: Entitlements in the Market
Kahneman, D., Knetsch, J. L., & Thaler, R. H. (2000) · Choices, Values, and Frames · doi:10.1017/cbo9780511803475.019 · Cited by 3,158
Medical Care Costs: How Much Welfare Loss?
Newhouse, J. P. (1992) · Journal of Economic Perspectives · doi:10.1257/jep.6.3.3 · Cited by 1,211
Patients’ expectations about effects of chemotherapy for advanced cancer
Weeks, J. C., Catalano, P. J., Cronin, A., Finkelman, M. D., Mack, J. W., Keating, N. L., & Schrag, D. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204410 · Cited by 1,149
Willingness to Pay for a Quality-adjusted Life Year: In Search of a Standard
Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000) · Medical Decision Making · doi:10.1177/0272989x0002000310 · Cited by 850
Journal of Clinical Oncology: One Year Old and Growing
(1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.1.1 · Cited by 688
Leukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
An Empirical Analysis of Latitude of Price Acceptance in Consumer Package Goods
Kalyanaram, G., & Little, J. D. C. (1994) · Journal of Consumer Research · doi:10.1086/209407 · Cited by 447
The Price Tag on Progress — Chemotherapy for Colorectal Cancer
Schrag, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048143 · Cited by 436
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Bach, P. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmhpr0807774 · Cited by 390
Self-citationGeneric Entry and the Pricing of Pharmaceuticals
Frank, R. G., & Salkever, D. S. (1997) · Journal of Economics & Management Strategy · doi:10.1111/j.1430-9134.1997.00075.x · Cited by 374
Pay, Reference Points, and Police Performance*
Mas, A. (2006) · Quarterly Journal of Economics · doi:10.1162/qjec.121.3.783 · Cited by 364
Cancer Drugs in the United States: Justum Pretium—The Just Price
Kantarjian, H. M., Fojo, T., Mathisen, M., & Zwelling, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1845 · Cited by 284
Rule-based price fairness and its effect on willingness to purchase
Maxwell, S. (2002) · Journal of Economic Psychology · doi:10.1016/s0167-4870(02)00063-6 · Cited by 271
Generic Entry and the Pricing of Pharmaceuticals
Frank, R. G., & Salkever, D. S. (1997) · Journal of Economics & Management Strategy · doi:10.1162/105864097567039 · Cited by 260
On the fairness of pricing — An empirical survey among the general population
Frey, B. S., & Pommerehne, W. W. (1993) · Journal of Economic Behavior & Organization · doi:10.1016/0167-2681(93)90027-m · Cited by 240
Information, marketing, and pricing in the U.S. antiulcer drug market.
Berndt, E. R., Bui, L. T. M., Reiley, D., & Urban, G. L. (1995) · PubMed · Cited by 187
Self-citationHow Medicare’s Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment
Jacobson, M., Earle, C. C., Price, M., & Newhouse, J. P. (2010) · Health Affairs · doi:10.1377/hlthaff.2009.0563 · Cited by 170
Roy, A. (1999) · Medical Entomology and Zoology · Cited by 169
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
Niraula, S., Seruga, B., Ocana, A., Shao, T., Goldstein, R., Tannock, I. F., & Amir, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3824 · Cited by 167
Does Reimbursement Influence Chemotherapy Treatment For Cancer Patients?
Jacobson, M., O’Malley, A. J., Earle, C. C., Pakes, J., Gaccione, P., & Newhouse, J. P. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.437 · Cited by 136
Lakdawalla, D., Romley, J. A., Sanchez, Y., Maclean, J. R., Penrod, J. R., & Philipson, T. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1300 · Cited by 132
Conti, R. M., Bernstein, A., Villaflor, V. M., Schilsky, R. L., Rosenthal, M. B., & Bach, P. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7252 · Cited by 127
Self-citation(1959) · Harvard University Press eBooks · doi:10.4159/harvard.9780674592711 · Cited by 120
Chapter 3 Medical care prices and output
Berndt, E. R., Cutler, D., Frank, R. G., Griliches, Z., Newhouse, J. P., & Triplett, J. E. (2000) · Handbook of health economics · doi:10.1016/s1574-0064(00)80162-6 · Cited by 87
Self-citationUsing Cost-Effectiveness Analysis to Improve Health Care
Neumann, P. J. (2004) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195171860.001.0001 · Cited by 74
The Value of Specialty Oncology Drugs
Goldman, D. P., Jena, A. B., Lakdawalla, D., Malin, J. L., Malkin, J. D., & Sun, E. C. (2009) · Health Services Research · doi:10.1111/j.1475-6773.2009.01059.x · Cited by 60
Are fairness constraints on profit-seeking important?
Piron, R., & Fernandez, L. (1995) · Journal of Economic Psychology · doi:10.1016/0167-4870(94)00037-b · Cited by 59
Cost Consequences of the 340B Drug Discount Program
Conti, R. M., & Bach, P. B. (2013) · JAMA · doi:10.1001/jama.2013.4156 · Cited by 53
Self-citationThe value of medical interventions for lung cancer in the elderly: Results from SEER‐CMHSF
Woodward, R. M., Brown, M. L., Stewart, S. T., Cronin, K. A., & Cutler, D. (2007) · Cancer · doi:10.1002/cncr.23058 · Cited by 50
The Value of New Chemotherapeutic Agents for Metastatic Colorectal Cancer
Howard, D. H. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.36 · Cited by 46
Self-citationNational estimates of medical costs incurred by nonelderly cancer patients
Howard, D. H., Molinari, N., & Thorpe, K. E. (2004) · Cancer · doi:10.1002/cncr.20063 · Cited by 42
Self-citationAn appeal to world leaders: stop cancer now
Cavalli, F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60059-8 · Cited by 42
Do Fixed Patent Terms Distort Innovation?: Evidence from Cancer Clinical TrialsPreprint
Budish, E. B., Roin, B. N., & Williams, H. (2013) · SSRN Electronic Journal · doi:10.2139/ssrn.2353471 · Cited by 38
Seabury, S. A., Goldman, D. P., Maclean, J. R., Penrod, J. R., & Lakdawalla, D. (2012) · Health Affairs · doi:10.1377/hlthaff.2012.0174 · Cited by 36
Lichtenberg, F. R. (2009) · Economics of Innovation and New Technology · doi:10.1080/10438590802547142 · Cited by 36
Howard, D. H., Kenline, C., Lazarus, H. M., LeMaistre, C. F., Maziarz, R. T., McCarthy, P. L., Parsons, S. K., Szwajcer, D., Rizzo, J., & Majhail, N. S. (2011) · Health Services Research · doi:10.1111/j.1475-6773.2011.01296.x · Cited by 32
Self-citation“Just Caring”: Can We Afford the Ethical and Economic Costs of Circumventing Cancer Drug Resistance?
Fleck, L. M. (2013) · Journal of Personalized Medicine · doi:10.3390/jpm3030124 · Cited by 31
Romley, J. A., Sanchez, Y., Penrod, J. R., & Goldman, D. P. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1301 · Cited by 24
Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis
Raborn, M. L., Pelletier, E. M., Smith, D. B., & Reyes, C. M. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000516 · Cited by 22
Pricing dynamics and product quality: the case of antidepressant drugs
Chen, J., & Rizzo, J. A. (2010) · Empirical Economics · doi:10.1007/s00181-010-0426-z · Cited by 11
Cited by
Carrera, P. M., Kantarjian, H. M., & Blinder, V. S. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21443 · Cited by 876
Cunningham, C., Ederer, F., & Ma, S. (2021) · Journal of Political Economy · doi:10.1086/712506 · Cited by 452
The high price of anticancer drugs: origins, implications, barriers, solutions
Prasad, V., De Jesús, K., & Mailankody, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.31 · Cited by 442
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360
Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies
Lentz, R., Benson, A. B., & Kircher, S. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25374 · Cited by 336
Metadata
- Authors
- Howard, D. H., Bach, P. B., Berndt, E. R., & Conti, R. M.
- Venue
- Journal of Economic Perspectives
- Publisher
- American Economic Association
- Published
- 2015-02-01
- Volume
- 29
- Issue
- 1
- Pages
- 139-162
- ISSN
- 0895-3309 (ISSN-L)
- OpenAlex
- W2143401180
- Cited by
- 444
- References
- 43
- FWCI
- 150.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.